Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C

Skolnik, Neil; Bonnes, Harmony; Yeh, H; Katz, Arie

doi:10.1080/00325481.2016.1173514

Cited by 9 publications

(5 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As reviewed previously in Drugs [4, 5], numerous randomized, double-blind, multicentre, phase 3 trials with dapagliflozin as monotherapy and combination therapy have demonstrated its efficacy in improving glycaemic control and reducing bodyweight and BP in a broad spectrum of patients with T2D, including those with high baseline HbA 1c (≥ 9%) [12] and the elderly (aged ≥ 65 years) [13]. Results from more recent trials, including special populations such as patients with chronic kidney disease (CKD) stage 3A [14], hypertension [15, 16] or CVD [17, 18], are summarized in Tables 1 and 2).…”

Section: Therapeutic Efficacy Of Dapagliflozinmentioning

confidence: 99%

Dapagliflozin: A Review in Type 2 Diabetes

Dhillon

2019

Drugs

150

View full text Add to dashboard Cite

Dapagliflozin (Forxiga ®) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone do not provide adequate glycaemic control. In numerous well-designed clinical studies and their extensions, dapagliflozin as monotherapy and combination therapy with other antihyperglycaemic agents provided effective glycaemic control and reduced bodyweight and blood pressure (BP) across a broad spectrum of patients. Dapagliflozin reduced the rate of cardiovascular (CV) death or hospitalization for heart failure (HHF), did not adversely affect major adverse CV events (MACE) and possibly reduced progression of renal disease relative to placebo in patients with established atherosclerotic CV disease (CVD) or multiple risk factors for CVD. Dapagliflozin was generally well tolerated, with a low risk of hypoglycaemia; diabetic ketoacidosis (DKA), although rare, and genital infections were more common with dapagliflozin than placebo. Given its antihyperglycaemic, cardioprotective and possibly renoprotective properties and generally favourable tolerability profile, dapagliflozin provides an important option for the management of a broad patient population, regardless of the history of CVD.

show abstract

Section: Therapeutic Efficacy Of Dapagliflozinmentioning

confidence: 99%

Dapagliflozin: A Review in Type 2 Diabetes

Dhillon

2019

Drugs

150

View full text Add to dashboard Cite

show abstract

“…Dapagliflozin is the first SGLT2 inhibitor demonstrated to clearly reduce hemoglobin A 1c (HbA 1c ) and fasting plasma glucose (FPG) in clinical therapy [18,19]. SGLT2 gene expression profiling demonstrated ubiquitous distribution in kidney, colon, and liver [20].…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

et al. 2017

View full text Add to dashboard Cite

BackgroundPatients with type 2 diabetes mellitus (T2DM) have a high incidence of renal cell carcinoma (RCC) and high sodium glucose co-transporters 2 (SGLT2) expressions. The purpose of this study was to evaluate the anticancer activity of dapagliflozin as an SGLT2 inhibitor on RCC cell lines in vitro and in vivo.Material/MethodsqRT-PCR and Western blot were used to detect SGLT2 expression on different human renal cells. Then, flow cytometry and immunofluorescence were used to investigate the effects of dapagliflozin on cell cycle, apoptosis, and SGLT2 expression of CaKi-1 cells. Finally, a xenograft model and immunohistochemical staining were used to investigate the function of dapagliflozin in nude mice.ResultsWe proved that SGLT2 is highly expressed in RCC cell lines. We found that dapagliflozin exerts a higher cytotoxic effect on human RCC than on normal human renal cells, regulates the cell cycle and apoptosis, and reduces the glucose uptake and SGLT2 expression of CaKi-1 cells. Moreover, dapagliflozin inhibits tumor growth and reduces SGLT2 expression in vivo.ConclusionsOur results indicate that dapagliflozin has high efficiency and low toxicity and could be a new therapeutic target for RCC.

show abstract

“…Furthermore, several systematic reviews and meta-analyses of RCTs reported that SGLT2i as monotherapy were efficacious, reduced body weight and BP, and were well tolerated by T2DM patients [ 48 – 52 ]. In addition, several RCTs also reported that SGLT2i were associated with clinically meaningful improvements in glycaemic parameters, and a reduction in body weight and BP in patients with baseline A1C ≥ 9% or ≥ 10% [ 53 – 55 ].…”

Section: Sglt2i and Diabetesmentioning

confidence: 99%

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Singh

Unnikrishnan²,

Zargar³

et al. 2019

Diabetes Ther

View full text Add to dashboard Cite

The current diabetes management strategies not only aim at controlling glycaemic parameters but also necessitate continuous medical care along with multifactorial risk reduction through a comprehensive management concept. The sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a group of evolving antidiabetic agents that have the potential to play a pivotal role in the comprehensive management of patients with diabetes due to their diverse beneficial effects. SGLT2i provide moderate glycaemic control, considerable body weight and blood pressure reduction, and thus have the ability to lower the risk of macrovascular and microvascular complications. Some of the unique characteristics associated with SGLT2i, such as reduction in body weight (more visceral fat mass loss than subcutaneous fat loss), reduction in insulin resistance and improvement in β-cell function, as measured by homeostatic model assessment-β (HOMA-β) could be potentially beneficial and help in overcoming some of the challenges faced by Indian patients with diabetes. In addition, a patient-centric approach with individualised treatment during SGLT2i therapy is inevitable in order to reduce diabetic complications and improve quality of life. Despite their broad benefits profile, the risk of genital tract infections, volume depletion, amputations and diabetic ketoacidosis associated with SGLT2i should be carefully monitored. In this compendium, we systematically reviewed the literature from Medline, Cochrane Library, and other relevant databases and attempted to provide evidence-based recommendations for the positioning of SGLT2i in the management of diabetes in the Indian population. Funding : AstraZeneca Pharma India Limited.

show abstract

Dapagliflozin in the treatment of patients with type 2 diabetes presenting with high baseline A1C

Cited by 9 publications

References 46 publications

Dapagliflozin: A Review in Type 2 Diabetes

Dapagliflozin: A Review in Type 2 Diabetes

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians

Contact Info

Product

Resources

About